Filing Flows

Filing Flows › Health Care › Davita (DVA)

Davita (DVA) earnings and revenue breakdown

Latest: Q3 2026 · 10-Q filed Oct 29, 2026 · Davita (DVA) Q3 2026 earnings results →

Q3 2026 Revenue up 5% year over year to $3.6B · 6¢ of every $1 of revenue kept as net profit · operating margin 14.0%

Davita made $3.6B in Q3 2026 (+5% Y/Y): U. S. Dialysis and Related Lab Services $3.0B, Other - Ancillary Services $550M. Operating margin 14.0%, net earnings $223M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 29, 2026.

Revenue$3.6B
Year over year+5%
Operating margin14.0%
Net earnings$223M
Operating cash flow$519M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

Davita Q3 2026 revenue breakdown: Sankey diagram of revenue (U. S. Dialysis and Related Lab Services, Other - Ancillary Services), costs, profit and cash flow
Davita Q3 2026 revenue breakdown — free to use with credit and a link (terms). Share on X
Embed this chart on your site

Free to use with the credit line. Click a box to select the code.

What changed this quarter

Revenue was $3.6B in Q3 2026, up 5% year over year and up 1% from the previous quarter. U. S. Dialysis and Related Lab Services was the largest line at 85% of revenue. Other - Ancillary Services added $0.10B year over year (up 22%), 62% of the total change.

Operating profit was $0.50B, a 14.0% margin (down 0.8 points year over year). Operating profit fell $0.01B even though revenue rose $0.16B versus Q3 2025, so costs grew faster than sales. Total costs grew 6% against revenue growth of 5%. Net earnings were $0.22B, up 48% year over year. The effective tax rate was 24.9%.

Operating cash flow was $0.52B (down 38% year over year), 193% of net income including minority interests. Non-cash charges added back $0.17B of depreciation and amortization and $0.03B of share-based compensation. Working capital and other items added $0.06B. After maintenance capital expenditures, net ($0.10B) and distributions to noncontrolling interests ($0.09B) and development capital expenditures ($0.05B), free cash flow as the company reports it was $0.28B.

Quarterly history

Davita revenue by quarterDavita revenue by quarter$3.2BQ1 2025$3.4BQ2 2025$3.4BQ3 2025$3.6BQ4 2025$3.4BQ1 2026$3.6BQ2 2026$3.6BQ3 2026
Davita net earnings by quarterDavita net earnings by quarter$163MQ1 2025$199MQ2 2025$150MQ3 2025$234MQ4 2025$198MQ1 2026$265MQ2 2026$223MQ3 2026
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q3 202610-QOct 29, 2026$3.6B+5%14.0%$223M$519M
Q2 202610-QAug 4, 2026$3.6B+5%16.3%$265M$490M
Q1 202610-QMay 5, 2026$3.4B+6%14.1%$198M$321M
Q4 202510-KFeb 11, 2026$3.6B+10%15.5%$234M$541M
Q3 202510-QOct 29, 2025$3.4B+5%14.8%$150M$842M
Q2 202510-QAug 5, 2025$3.4B+6%15.9%$199M$324M
Q1 202510-QMay 12, 2025$3.2B+5%13.6%$163M$180M

Charts

Davita: revenue growth, year over year and quarter over quarterDavita: revenue growth, year over year and quarter over quarterY/YQ/Q+5%Q1 2025+6%+5%Q2 2025+5%+1%Q3 2025+10%+6%Q4 2025+6%-6%Q1 2026+5%+4%Q2 2026+5%+1%Q3 2026
Latest (Q3 2026): Y/Y +5%, Q/Q +1%.
Davita: where the cash came from (+) and went (−), TTM to Q3 2026Davita: where the cash came from (+) and went (−), TTM to Q3 2026Operating cash flow$1.9BOther financing−$819MBuybacks−$725MCapital spending−$577MNet borrowing (+) / repaid (−)$522MOther investing−$358MCash drawn (+) / kept (−)$216MPartners−$76.6MTaxes on employees’ shares−$70.5MAsset & business sales$18.1MNot reconciled−$855K
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Davita: profit against cash, quarter by quarterDavita: profit against cash, quarter by quarterNet incomeOperating cash flow$349M$548MQ4 2024$232M$180MQ1 2025$275M$324MQ2 2025$240M$842MQ3 2025$331M$541MQ4 2025$275M$321MQ1 2026$343M$490MQ2 2026$269M$519MQ3 2026
Latest (Q3 2026): Net income $269M, Operating cash flow $519M.
Davita: diluted shares by fiscal yearDavita: diluted shares by fiscal year123MFY2020110MFY202196MFY202293MFY202387MFY202476MFY2025
-38.1% since FY2020: buybacks shrank the count.
Davita: long-term debt falling due (FY2025)Davita: long-term debt falling due (FY2025)$109M2026$110M2027$150M2028$142M2029$4.5B2030$5.3BLater
Cash $676M, short-term investments $24.3M, long-term debt $10.3B at 2025-12-31.
Davita in its industry: growth against margin (10 companies, SIC 8090)Davita in its industry: growth against margin (10 companies, SIC 8090)revenue growth, year over year →↑ operating marginmedian +5%median 9%AGLPGNYSHCVMDPARKCCELMRAIPFHOMGRXDVA (+5%, 14%)
Services-Misc Health & Allied Services, NEC; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

Customers and suppliers named in filings

Buys from

About Davita

Unless otherwise indicated in this report "DaVita", "the Company" "we", "us", "our" and other similar terms refer to DaVita Inc. and its consolidated subsidiaries. Our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, are made available free of charge through our website, located at http://www.davita.com , as soon as reasonably practicable after the reports are filed with or furnished to the Securities and Exchange Commission (SEC). The SEC also maintains a website at http://www.sec.gov where these reports and other information about us can be obtained. The contents of our website are not incorporated by reference into this report.

In its own words, from its 10-K, filed Feb 11, 2026.

Davita against its Services-Misc Health & Allied Services, NEC peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +5% against the peers' median +5%. Operating margin: 14.0% against the peers' median 8.9%.

CompanyQuarterRevenueY/YOp. margin
DVA DavitaQ3 2026$3.6B+5%14.0%
AGL agilon healthQ3 2026$1.5B+6%1.6%
PGNY ProgynyQ3 2026$341M+9%10.3%
SHC Sotera HealthQ3 2026$325M+4%25.8%
VMD Viemed HealthcareQ3 2026$80.7M+12%8.6%
PARK Park Dental PartnersQ2 2026$66.2M+5%1.9%
CCEL Cryo Cell InternationalQ3 FY26$7.8M0%28.0%
MRAI MarpaiQ2 2026$4.2M-10%-82.4%
PFHO Pacific Health Care OrganizationQ3 2026$1.5M-5%8.9%

Source: Davita 10-Q on SEC EDGAR · CIK 927066 · Services-Misc Health & Allied Services, NEC

13F: who owns DVA and who is buying

Largest holders of DVA (13F)Largest holders of DVA (13F)Berkshire Hathaway$6.4BBlackRock$548MVanguard Group$472MVanguard Capital Management LLC$468MMorgan Stanley$356MVanguard Portfolio Management LLC$307MState Street$294MInvesco$270MDimensional Fund Advisors LP$253MNeuberger Berman Group LLC$206M
Funds' net buying of DVA by quarter (13F)Funds' net buying of DVA by quarter (13F)−$162M2024-09$33.6M2024-12−$378M2025-03−$62.6M2025-06−$423M2025-09−$75.4M2025-12−$613M2026-03−$707M2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on DVA

History

Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results

Compare DVA with

中文版：Davita（DVA）财报

Español · Français